FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3119197087> ?p ?o ?g. }

• W3119197087 endingPage "1900" @default.
• W3119197087 startingPage "1894" @default.
• W3119197087 abstract "New drug combinations have led to significant improvements in remission rates for patients with acute myeloid leukemia (AML). However, many patients with high-risk AML who respond to their initial treatment and are not candidates for allogeneic stem cell transplantation (ASCT) will eventually relapse with poor outcomes.In this phase 2 trial, the efficacy of lenalidomide maintenance was evaluated in patients with high-risk AML who had achieved their first or second remission after induction chemotherapy and at least 1 consolidation cycle and who were not candidates for immediate ASCT. Lenalidomide was given orally at 10 to 20 mg daily on days 1 to 28 of a 28-day cycle for up to 24 cycles.A total of 28 patients were enrolled in this study with a median age of 61 years (range, 24-87 years). The median number of cycles was 8 (range, 1-24 cycles). Ten patients (36%) completed 24 months of maintenance treatment. With a median follow-up of 22.5 months (range, 2.6-55 months), 12 patients (43%) relapsed after a median of 3 months (range, 0.7-23 months). The median duration of remission for all patients was 18.7 months (range, 0.7-55.1 months). The 2-year overall survival and relapse-free survival rates from the time of enrollment were 63% and 50%, respectively. Overall, lenalidomide was well tolerated; serious adverse events of grade 3 or 4, including rash (n = 5), thrombocytopenia (n = 4), neutropenia (n = 4), and fatigue (n = 2), were observed in 13 patients (46%).Lenalidomide is a safe and feasible maintenance strategy in patients with high-risk AML who are not candidates for ASCT, and it has beneficial effects for patients with negative measurable residual disease." @default.
• W3119197087 created "2021-01-18" @default.
• W3119197087 creator A5000750846 @default.
• W3119197087 creator A5015140142 @default.
• W3119197087 creator A5020340537 @default.
• W3119197087 creator A5021380291 @default.
• W3119197087 creator A5028845635 @default.
• W3119197087 creator A5030500582 @default.
• W3119197087 creator A5035605515 @default.
• W3119197087 creator A5046135731 @default.
• W3119197087 creator A5049385583 @default.
• W3119197087 creator A5054907494 @default.
• W3119197087 creator A5055045706 @default.
• W3119197087 creator A5061026876 @default.
• W3119197087 creator A5062980576 @default.
• W3119197087 creator A5069176297 @default.
• W3119197087 creator A5077187052 @default.
• W3119197087 creator A5079262854 @default.
• W3119197087 creator A5083793750 @default.
• W3119197087 creator A5084290698 @default.
• W3119197087 creator A5088307376 @default.
• W3119197087 creator A5089295627 @default.
• W3119197087 creator A5090435894 @default.
• W3119197087 date "2021-01-15" @default.
• W3119197087 modified "2023-10-15" @default.
• W3119197087 title "Phase 2 study of lenalidomide maintenance for patients with high‐risk acute myeloid leukemia in remission" @default.
• W3119197087 cites W1920829940 @default.
• W3119197087 cites W1970610464 @default.
• W3119197087 cites W1980068016 @default.
• W3119197087 cites W1986769067 @default.
• W3119197087 cites W2017224680 @default.
• W3119197087 cites W2034295250 @default.
• W3119197087 cites W2040596732 @default.
• W3119197087 cites W2049533509 @default.
• W3119197087 cites W2049869153 @default.
• W3119197087 cites W2074425311 @default.
• W3119197087 cites W2118270328 @default.
• W3119197087 cites W2148047805 @default.
• W3119197087 cites W2162700652 @default.
• W3119197087 cites W2276580523 @default.
• W3119197087 cites W2296458069 @default.
• W3119197087 cites W2559537906 @default.
• W3119197087 cites W2566202363 @default.
• W3119197087 cites W2620608553 @default.
• W3119197087 cites W2737964630 @default.
• W3119197087 cites W2807921412 @default.
• W3119197087 cites W2887033855 @default.
• W3119197087 cites W2896426525 @default.
• W3119197087 cites W2909763242 @default.
• W3119197087 cites W2969998705 @default.
• W3119197087 cites W2989764345 @default.
• W3119197087 cites W4231346141 @default.
• W3119197087 doi "https://doi.org/10.1002/cncr.33409" @default.
• W3119197087 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33449377" @default.
• W3119197087 hasPublicationYear "2021" @default.
• W3119197087 type Work @default.
• W3119197087 sameAs 3119197087 @default.
• W3119197087 citedByCount "6" @default.
• W3119197087 countsByYear W31191970872022 @default.
• W3119197087 countsByYear W31191970872023 @default.
• W3119197087 crossrefType "journal-article" @default.
• W3119197087 hasAuthorship W3119197087A5000750846 @default.
• W3119197087 hasAuthorship W3119197087A5015140142 @default.
• W3119197087 hasAuthorship W3119197087A5020340537 @default.
• W3119197087 hasAuthorship W3119197087A5021380291 @default.
• W3119197087 hasAuthorship W3119197087A5028845635 @default.
• W3119197087 hasAuthorship W3119197087A5030500582 @default.
• W3119197087 hasAuthorship W3119197087A5035605515 @default.
• W3119197087 hasAuthorship W3119197087A5046135731 @default.
• W3119197087 hasAuthorship W3119197087A5049385583 @default.
• W3119197087 hasAuthorship W3119197087A5054907494 @default.
• W3119197087 hasAuthorship W3119197087A5055045706 @default.
• W3119197087 hasAuthorship W3119197087A5061026876 @default.
• W3119197087 hasAuthorship W3119197087A5062980576 @default.
• W3119197087 hasAuthorship W3119197087A5069176297 @default.
• W3119197087 hasAuthorship W3119197087A5077187052 @default.
• W3119197087 hasAuthorship W3119197087A5079262854 @default.
• W3119197087 hasAuthorship W3119197087A5083793750 @default.
• W3119197087 hasAuthorship W3119197087A5084290698 @default.
• W3119197087 hasAuthorship W3119197087A5088307376 @default.
• W3119197087 hasAuthorship W3119197087A5089295627 @default.
• W3119197087 hasAuthorship W3119197087A5090435894 @default.
• W3119197087 hasBestOaLocation W31191970871 @default.
• W3119197087 hasConcept C126322002 @default.
• W3119197087 hasConcept C141071460 @default.
• W3119197087 hasConcept C197934379 @default.
• W3119197087 hasConcept C2776063141 @default.
• W3119197087 hasConcept C2776364478 @default.
• W3119197087 hasConcept C2776694085 @default.
• W3119197087 hasConcept C2777063308 @default.
• W3119197087 hasConcept C2778283404 @default.
• W3119197087 hasConcept C2778570526 @default.
• W3119197087 hasConcept C71924100 @default.
• W3119197087 hasConceptScore W3119197087C126322002 @default.
• W3119197087 hasConceptScore W3119197087C141071460 @default.
• W3119197087 hasConceptScore W3119197087C197934379 @default.
• W3119197087 hasConceptScore W3119197087C2776063141 @default.
• W3119197087 hasConceptScore W3119197087C2776364478 @default.

• next